Nat Cell Biol:AMPK调控Hippo通路对肿瘤的能量代谢至关重要

2015-03-12 生物谷 生物谷

为何细胞信号通路对于癌症研究非常重要,因为其会影响到下游的一切事件,进而影响到癌症的进展,信号通路中的某一个分子一旦被激活就会导致另一个也被激活,从引发级联反应,在机体中形成巨大的反应,就比如在癌症发生过程中细胞分解血糖为肿瘤生长提供能量。 近日,来自得克萨斯大学的研究人员通过研究发现,一种名为Hippo(河马)的信号通路或许可以调节细胞的死亡和生长,从而在肿瘤的发展和预防过程中扮演重要角色,相

为何细胞信号通路对于癌症研究非常重要,因为其会影响到下游的一切事件,进而影响到癌症的进展,信号通路中的某一个分子一旦被激活就会导致另一个也被激活,从引发级联反应,在机体中形成巨大的反应,就比如在癌症发生过程中细胞分解血糖为肿瘤生长提供能量。

近日,来自得克萨斯大学的研究人员通过研究发现,一种名为Hippo(河马)的信号通路或许可以调节细胞的死亡和生长,从而在肿瘤的发展和预防过程中扮演重要角色,相关研究刊登于国际杂志Nature Cell Biology上。研究者Junjie Chen表示,我们的研究揭示了河马信号通路或许可以被操纵来调节葡萄糖的代谢,从而为开发癌症疗法提供新的线索。

研究者在研究中鉴别出了葡萄糖代谢和河马通路之间的交联过程,此前研究中研究者并不清楚河马通路在葡萄糖代谢过程中的作用,但本文研究却建立了河马信号通路和机体葡萄糖代谢之间的关系。换句话说,如今研究者知道如何通过利用调节河马通路来调节机体的血糖代谢,从而影响肿瘤的营养和能量供给。

研究者表示,有两种关键的蛋白,即YAP和AMPK参与了一系列信号级联事件,YAP可以促进癌症进展及癌症转移,研究者发现,当细胞处于缺乏葡萄糖状态下,AMPK酶类就会被激活,从而促进YAP蛋白失活;而YAP的调节也可以通过一种GLUT3基因的部分调节来完成,该基因主要参与葡萄糖代谢,研究结果发现,YAP蛋白在河马通路和促进癌症扩散的细胞代谢中扮演着上游调节的角色。

AMPK对YAP蛋白的效应可以帮助研究人员深入理解YAP的调节机制,而本文却揭示了YAP的另外一个癌症相关的功能,这就为清楚地解析河马通路和葡萄糖代谢在组织维护和癌症预防过程中的关系提供了新的研究思路。肿瘤细胞通常被认为可以对信号通路和代谢进行重编程来支持自身的无限生长,而研究人员则希望通过后期研究发现更多促进癌症转移的新型蛋白,从而为开发癌症靶向疗法带来帮助。

原始出处:

Wang W, Xiao ZD, Li X, Aziz KE, Gan B, Johnson RL, Chen J.AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat Cell Biol. 2015 Mar 9. doi: 10.1038/ncb3113. 

Mo JS, Meng Z, Kim YC, Park HW, Hansen CG, Kim S, Lim DS, Guan KL.Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway.Nat Cell Biol. 2015 Mar 9. doi: 10.1038/ncb3111.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959291, encodeId=07751959291dd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 12 15:39:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880540, encodeId=bb59188054079, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 28 11:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766935, encodeId=b77b1e6693528, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Apr 18 01:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869040, encodeId=0a701869040a0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 03 21:39:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057854, encodeId=190e205e854dd, content=<a href='/topic/show?id=0aea886248' target=_blank style='color:#2F92EE;'>#Hippo通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8862, encryptionId=0aea886248, topicName=Hippo通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 13 16:39:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917138, encodeId=5840191e138b1, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 16 22:39:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492705, encodeId=c80c1492e051d, content=<a href='/topic/show?id=7050842e999' target=_blank style='color:#2F92EE;'>#能量代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84279, encryptionId=7050842e999, topicName=能量代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b18951187, createdName=amyloid, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
    2016-01-12 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959291, encodeId=07751959291dd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 12 15:39:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880540, encodeId=bb59188054079, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 28 11:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766935, encodeId=b77b1e6693528, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Apr 18 01:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869040, encodeId=0a701869040a0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 03 21:39:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057854, encodeId=190e205e854dd, content=<a href='/topic/show?id=0aea886248' target=_blank style='color:#2F92EE;'>#Hippo通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8862, encryptionId=0aea886248, topicName=Hippo通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 13 16:39:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917138, encodeId=5840191e138b1, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 16 22:39:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492705, encodeId=c80c1492e051d, content=<a href='/topic/show?id=7050842e999' target=_blank style='color:#2F92EE;'>#能量代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84279, encryptionId=7050842e999, topicName=能量代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b18951187, createdName=amyloid, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
    2015-05-28 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959291, encodeId=07751959291dd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 12 15:39:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880540, encodeId=bb59188054079, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 28 11:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766935, encodeId=b77b1e6693528, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Apr 18 01:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869040, encodeId=0a701869040a0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 03 21:39:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057854, encodeId=190e205e854dd, content=<a href='/topic/show?id=0aea886248' target=_blank style='color:#2F92EE;'>#Hippo通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8862, encryptionId=0aea886248, topicName=Hippo通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 13 16:39:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917138, encodeId=5840191e138b1, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 16 22:39:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492705, encodeId=c80c1492e051d, content=<a href='/topic/show?id=7050842e999' target=_blank style='color:#2F92EE;'>#能量代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84279, encryptionId=7050842e999, topicName=能量代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b18951187, createdName=amyloid, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959291, encodeId=07751959291dd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 12 15:39:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880540, encodeId=bb59188054079, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 28 11:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766935, encodeId=b77b1e6693528, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Apr 18 01:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869040, encodeId=0a701869040a0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 03 21:39:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057854, encodeId=190e205e854dd, content=<a href='/topic/show?id=0aea886248' target=_blank style='color:#2F92EE;'>#Hippo通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8862, encryptionId=0aea886248, topicName=Hippo通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 13 16:39:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917138, encodeId=5840191e138b1, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 16 22:39:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492705, encodeId=c80c1492e051d, content=<a href='/topic/show?id=7050842e999' target=_blank style='color:#2F92EE;'>#能量代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84279, encryptionId=7050842e999, topicName=能量代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b18951187, createdName=amyloid, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1959291, encodeId=07751959291dd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 12 15:39:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880540, encodeId=bb59188054079, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 28 11:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766935, encodeId=b77b1e6693528, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Apr 18 01:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869040, encodeId=0a701869040a0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 03 21:39:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057854, encodeId=190e205e854dd, content=<a href='/topic/show?id=0aea886248' target=_blank style='color:#2F92EE;'>#Hippo通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8862, encryptionId=0aea886248, topicName=Hippo通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 13 16:39:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917138, encodeId=5840191e138b1, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 16 22:39:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492705, encodeId=c80c1492e051d, content=<a href='/topic/show?id=7050842e999' target=_blank style='color:#2F92EE;'>#能量代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84279, encryptionId=7050842e999, topicName=能量代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b18951187, createdName=amyloid, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1959291, encodeId=07751959291dd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 12 15:39:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880540, encodeId=bb59188054079, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 28 11:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766935, encodeId=b77b1e6693528, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Apr 18 01:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869040, encodeId=0a701869040a0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 03 21:39:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057854, encodeId=190e205e854dd, content=<a href='/topic/show?id=0aea886248' target=_blank style='color:#2F92EE;'>#Hippo通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8862, encryptionId=0aea886248, topicName=Hippo通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 13 16:39:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917138, encodeId=5840191e138b1, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 16 22:39:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492705, encodeId=c80c1492e051d, content=<a href='/topic/show?id=7050842e999' target=_blank style='color:#2F92EE;'>#能量代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84279, encryptionId=7050842e999, topicName=能量代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b18951187, createdName=amyloid, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]
    2015-06-16 sunylz
  7. [GetPortalCommentsPageByObjectIdResponse(id=1959291, encodeId=07751959291dd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jan 12 15:39:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880540, encodeId=bb59188054079, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 28 11:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766935, encodeId=b77b1e6693528, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Apr 18 01:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869040, encodeId=0a701869040a0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 03 21:39:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057854, encodeId=190e205e854dd, content=<a href='/topic/show?id=0aea886248' target=_blank style='color:#2F92EE;'>#Hippo通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8862, encryptionId=0aea886248, topicName=Hippo通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 13 16:39:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917138, encodeId=5840191e138b1, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 16 22:39:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492705, encodeId=c80c1492e051d, content=<a href='/topic/show?id=7050842e999' target=_blank style='color:#2F92EE;'>#能量代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84279, encryptionId=7050842e999, topicName=能量代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b18951187, createdName=amyloid, createdTime=Sat Mar 14 00:39:00 CST 2015, time=2015-03-14, status=1, ipAttribution=)]

相关资讯

那些与炎症密切相关的肿瘤

肿瘤组织中存在免疫细胞浸润 炎症与肿瘤的关系最早引起研究者的关注,是因为人们在肿瘤的标本中发现了免疫细胞浸润。当时这个现象大多被解释成为机体免疫系统对肿瘤细胞的应答,但是德国的菲尔绍(Virchow)教授却提出了不同意见,认为“肿瘤起源于慢性炎症”。此外,在肿瘤中发现的免疫细胞类型与非肿瘤性炎症部位的细胞一致,因此当时病理学家将肿瘤称为“永不愈合的创伤”。此后越来越多的科学家深入研究

ASCO GU 2015:泌尿生殖系肿瘤免疫靶向药物的疗效和耐药机制

免疫靶向治疗在多种实体瘤和淋巴瘤中取得了较好的疗效,在泌尿系肿瘤中也取得了突破性进展。如,在晚期尿路上皮癌中,程序性死亡分子1(PD-1)抗体pembrolizumab(keytruda)和PD-1配体(PD-L1)抗体MPDL3280A在PD-L1表达阳性患者中的客观有效率为25%~53%,在PD-L1表达阴性患者中为13%。因此,美国食品与药物管理局(FDA)授予MPDL3280A治疗转移性尿

突破、完善与希望:胰岛素治疗90年

自1889年,Oskar Minkowski等初次发现胰腺和糖尿病之间的关系后,胰岛细胞(islet of Langerhans)与糖尿病的关系逐渐明朗。 1921年,Frederick Banting、Charls Best、John Macleod及James Collip共同协作提纯了牛胰岛素,并于1922年首次成功救治糖尿病患者。次年,礼来公司开始量化生产高纯度牛胰岛素并迅速应用于

抗肿瘤/免疫/心血管等领域全球药企25强销售排名

全球制药企业排名榜单并不鲜见,每年各大公司年报一经发布,便有研究机构会统计其销售额并进行业绩排名。但如果把各公司销售业绩再拆分,细分不同的治疗领域进行排名,则并不常见。本文我们将为大家介绍抗肿瘤、免疫系统疾病、代谢疾病等主要治疗领域全球制药企业2013年销售额排名情况,供大家参考。本文数据由GlobalData统计处理,金额单位百万美元。抗肿瘤领域抗肿瘤药物领域,罗氏(Roche)公司可谓一家独大

Oral Oncol:既往癌症史对头颈癌的影响

Oral Oncol:既往癌症史对头颈癌的影响关键词:头颈癌 存活 肿瘤 第二原发癌引言由于癌症的早期检查以及先进的癌症治疗技术,癌症患者生存率逐步提高,但是癌症患者生存率面临着一个日益严重的风险——二次原发癌(SPC)发病率的不断升高。特别是,与一般人群相比,患者第一次原发癌是由于吸烟、喝酒所引起的(如肺癌、食道癌、头颈癌等),他们发生头颈部SPC的风险较高。大多数SPCs是头颈部鳞状细胞癌(H

iKnife电子手术刀,可能精准切除肿瘤

针对癌症患者,医生们永远是希望能够提高手术时对癌变组织进行的辨识准确度,现在我们可以说有了很好的解决方案,因为电子手术刀已经问世了。iknife电子手术刀是英国教授发明的一种新型的能够精确识别癌变组织细胞的手术刀,通过科技技术可以辅助医师在手术过程中能够更好地切除癌症病变组织,为患者的健康康复进行努力。 英国帝国理工学院的教授Zoltan Takats说道,尝试摘除癌组织就像是闭眼开车一样难以做